Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History

• Published in: International journal of molecular sciences Vol. 22; no. 5; p. 2596
• Main Authors: Kaneto, Hideaki, Kimura, Tomohiko, Obata, Atsushi, Shimoda, Masashi, Kaku, Kohei
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.03.2021; MDPI
• Subjects: Antidiabetics; Apoptosis; Arteriosclerosis; Autophagy - drug effects; Biosynthesis; Cell growth; Clinical medicine; COVID-19 - complications; COVID-19 - mortality; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - etiology; Diabetes Mellitus, Type 2 - mortality; Digestive system; Drugs; Gastrointestinal Microbiome - drug effects; Glucagon; Glucose; Humans; Hyperglycemia; Hypoxia; Insulin resistance; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Intracellular Signaling Peptides and Proteins - drug effects; Intracellular Signaling Peptides and Proteins - metabolism; Ischemia; Kinases; Liver; Metformin - pharmacology; Microbiota; Musculoskeletal system; Nitric oxide; Peptides; Proteins; Review; Transcription factors; COVID-19; autophagy; gut microbiome; GDF15; glucagon signaling; mTOR; AMPK; metformin
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22052596

While there are various kinds of drugs for type 2 diabetes mellitus at present, in this review article, we focus on metformin which is an insulin sensitizer and is often used as a first-choice drug worldwide. Metformin mainly activates adenosine monophosphate-activated protein kinase (AMPK) in the liver which leads to suppression of fatty acid synthesis and gluconeogenesis. Metformin activates AMPK in skeletal muscle as well, which increases translocation of glucose transporter 4 to the cell membrane and thereby increases glucose uptake. Further, metformin suppresses glucagon signaling in the liver by suppressing adenylate cyclase which leads to suppression of gluconeogenesis. In addition, metformin reduces autophagy failure observed in pancreatic β-cells under diabetic conditions. Furthermore, it is known that metformin alters the gut microbiome and facilitates the transport of glucose from the circulation into excrement. It is also known that metformin reduces food intake and lowers body weight by increasing circulating levels of the peptide hormone growth/differentiation factor 15 (GDF15). Furthermore, much attention has been drawn to the fact that the frequency of various cancers is lower in subjects taking metformin. Metformin suppresses the mechanistic target of rapamycin (mTOR) by activating AMPK in pre-neoplastic cells, which leads to suppression of cell growth and an increase in apoptosis in pre-neoplastic cells. It has been shown recently that metformin consumption potentially influences the mortality in patients with type 2 diabetes mellitus and coronavirus infectious disease (COVID-19). Taken together, metformin is an old drug, but multifaceted mechanisms of action of metformin have been unraveled one after another in its long history.